The sciatica market is estimated to be valued at US$ 6962.2 Mn in 2023 and is expected to exhibit a CAGR of 5.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Sciatica refers to pain that radiates along the path of the sciatic nerve, which branches from the lower back through the hips and buttocks and down each leg. Typically, only one side of the body is affected. The main causes of sciatica include herniated discs, spinal stenosis, and piriformis syndrome. Products available in the sciatica market include nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, anticonvulsants, and local anesthetics. These drugs help reduce inflammation, muscle spasms, and pain associated with sciatica.

Market Dynamics:
The sciatica market is primarily driven by the increasing geriatric population worldwide who are prone to developing back problems. As per the United Nations, the population aged 60 years and older is expected to double from 12% to 22% between 2015 and 2050 worldwide. Moreover, increasing prevalence of obesity is another factor augmenting market growth. Rising obese population has led to a surge in lower back issues which could give rise to sciatica. According to WHO, global prevalence of obesity nearly tripled between 1975 to 2016. Additionally, growing awareness regarding availability of treatment options is creating a positive impact on the market. However, risks and complications associated with long-term usage of pain medication is expected to hinder market growth over the forecast period.


SWOT Analysis

Strengths:
- Growing geriatric population is more prone to sciatica due to age related changes in spine and muscles.
- Increasing awareness regarding treatment options available for sciatica and nerve pains.
- Availability of generic drugs providing cost effective treatment options.

Weaknesses:
- Limited research on sciatica causes long term side effects of available treatment options.
- Sciatica symptoms vary from person to person making it difficult to standardize treatment options.

Opportunities:
- Emerging economies provide significant growth opportunities due to growing medical needs of large population base.
- Ongoing research on novel drug molecules and treatment modalities can expand available treatment options.

Threats:
- High costs associated with new drug development can increase treatment costs.
- Alternative treatment options like physiotherapy poses threat to pharmaceutical treatment sales.

Key Takeaways

The global Sciatica market is expected to witness high growth, exhibiting CAGR of 5.1% over the forecast period, due to increasing prevalence of musculoskeletal disorders and growing geriatric population globally.

Regional analysis:
North America region currently dominates the global sciatica market due to growing elderly population and increased spending on healthcare. Asia Pacific region is expected to witness fastest growth due to large patient pool, growing medical needs of dominating population and increasing healthcare spending in countries like China and India.

Key players analysis:
Key players operating in the sciatica market are Sorrento Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Jubilant Life Sciences Ltd., Hikma Pharmaceuticals PLC., Mylan N.V., Horizon Therapeutics Plc., Sun Pharmaceutical Industries Ltd., Alkem Labs, SCILEX Pharmaceuticals, Inc., Seikagaku Corporation, Kolon Life Science, Inc., Teijin Limited, and SpineThera, Inc.